Registry for patients treated with ion beam radiation therapy
Official title: A Prospective Registry Study to Record Clinical Results and Side Effects of Ion Beam Therapy at MedAustron
Run by EBG MedAustron GmbH · NCT03049072 · Data updated 2026-11-12
This study is collecting information from patients getting ion beam radiation therapy to see how well it works and how it affects their health and quality of life over time.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 2800 (estimated) |
| Sponsor | EBG MedAustron GmbH Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 1 site (Wiener Neustadt, Lower Austria) |
| Status | Recruiting |
| Started | December 2016 |
| Main results expected | December 2031 |
| Study ends | December 2036 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT03049072 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with tumor diseases who are being treated with ion beam therapy at MedAustron.
✕Probably not a fit
Patients with comorbidities that could jeopardize treatment delivery or compliance may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect standardized data from patients undergoing ion beam radiation therapy at MedAustron. It will track tumor control, treatment responses, and both acute and late toxicities over a period of up to 10 years. Additionally, the study will assess quality of life, sociodemographic factors, and perform neurocognitive evaluations for patients receiving brain radiation. The goal is to gather comprehensive information to improve future treatment protocols.
Why it matters
Potential benefit: If successful, this study could enhance understanding of ion therapy's effectiveness and safety, leading to improved patient outcomes.
How similar studies have gone: While this study focuses on a specific treatment modality, similar observational studies have shown success in improving treatment protocols and patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with tumor disease treated with ion beam therapy at MedAustron * Signed informed consent form Exclusion Criteria: * Comorbidities endangering treatment delivery or study compliance
Where it's running
-
EBG MedAustron GmbH
Wiener Neustadt, Lower Austria, Austria Recruiting
Study contacts
- Principal investigator: Yvonne Goy, MD — EBG MedAustron GmbH
- Study coordinator: Yvonne Goy, MD
- Email: yvonne.goy@medaustron.at
- Phone: +43 2622 26 100
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High dose short course radiotherapy for locally advanced pancreatic cancer
This study is testing a new type of high-dose radiation therapy for people with locally advanced pancreatic cancer to see how well it works when combined with standard treatments.
-
Combining proton therapy and chemotherapy for borderline resectable pancreatic cancer
This study is testing whether combining chemotherapy with proton therapy before surgery can help people with borderline resectable pancreatic cancer have better outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.